Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec:110:103878.
doi: 10.1016/j.drugpo.2022.103878. Epub 2022 Oct 12.

Modelling the contribution of incarceration and public health oriented drug law reform to HCV transmission and elimination among PWID in Tijuana, Mexico

Carlos D Rivera Saldana  1 , Leo Beletsky  2 , Annick Borquez  3 , Susan M Kiene  4 , Lara K Marquez  3 , Steffanie A Strathdee  3 , María Luisa Zúñiga  5 , Javier Cepeda  6 , Natasha K Martin  7
Affiliations

Modelling the contribution of incarceration and public health oriented drug law reform to HCV transmission and elimination among PWID in Tijuana, Mexico

Carlos D Rivera Saldana et al. Int J Drug Policy. 2022 Dec.

Abstract

Background: Incarceration is associated with increased risk of hepatitis C virus (HCV) among people who inject drugs (PWID). Mexico's previous attempt in implementing a public health-oriented drug law reform resulted in minimal impact on incarceration among PWID. However, implementation of reforms alongside Mexico's HCV elimination program has the potential to reshape the HCV epidemic among PWID in the next decade. We use data from a cohort of PWID in Tijuana, Mexico, to inform epidemic modeling to assess the contribution of incarceration and fully implemented drug reform on HCV transmission and elimination among PWID.

Methods: We developed a dynamic, deterministic model of incarceration, HCV transmission and disease progression among PWID. The model was calibrated to data from Tijuana, Mexico, with 90% HCV seroprevalence among 10,000 PWID. We estimated the 10-year population attributable fraction (PAF) of incarceration to HCV incidence among PWID and simulated, from 2022, the potential impact of the following scenarios: 1) decriminalization (80% reduction in incarceration rates); 2) fully implemented drug law reform (decriminalization and diversion to opiate agonist therapy [OAT]); 3) fully implemented drug law reform with HCV treatment (direct-acting antivirals [DAA]). We also assessed the number DAA needed to reach the 80% incidence reduction target by 2030 under these scenarios.

Results: Projections suggest a PAF of incarceration to HCV incidence of 5.4% (95% uncertainty interval [UI]:0.6-11.9%) among PWID in Tijuana between 2022-2032. Fully implemented drug reforms could reduce HCV incidence rate by 10.6% (95%UI:3.1-19.2%) across 10 years and reduce the number of DAA required to achieve Mexico's HCV incidence reduction goal by 14.3% (95%UI:5.3-17.1%).

Conclusions: Among PWID in Tijuana, Mexico, incarceration remains an important contributor to HCV transmission. Full implementation of public health-oriented drug law reform could play an important role in reducing HCV incidence and improve the feasibility of reaching the HCV incidence elimination target by 2030.

Keywords: Drug law reform; Epidemic modelling; HCV; Incarceration; PWID.

PubMed Disclaimer

Conflict of interest statement

Declarations of Interest N.M. has received unrestricted research grants from Gilead and Merck unrelated to this work.

Figures

Fig. 1.
Fig. 1.
Hepatitis C virus model schematic. PWID=people who inject drugs. OAT=opioid agonist therapy. Schematic’s symbols defined in Table 1.
Fig. 2.
Fig. 2.
Incarceration submodel schematic*. Ref=reference category. RR=relative risk. PWID=people who inject drugs. p6m=past 6 months. 6m=6months. CI=confidence interval.
Fig. 3.
Fig. 3.
Model fit to observed HCV chronic prevalence: Projected vs. observed proportion of PWID chronically infected with HCV at baseline (2022). PWID= People who inject drugs. CI=confidence interval. UI= Uncertainty interval.
Fig. 4.
Fig. 4.
Relative reduction in Hepatitis C virus (HCV) incidence rate among people who inject drugs (PWID) in Tijuana, Mexico for different intervention scenarios compared to baseline 2022–2032. DAA=direct acting antivirals.
Fig. 5.
Fig. 5.
Mean Hepatitis C virus (HCV) incidence projection for people who inject drugs (PWID) in Tijuana, Mexico by intervention combination. DAA=direct acting antivirals. Py=person years.
Fig. 6.
Fig. 6.
First year Hepatitis C virus (HCV) treatment numbers needed to meet World Health Organization (WHO) HCV incidence reduction (80%) target by 2030 among people who inject drugs (PWID) in Tijuana, Mexico DAA=direct acting antivirals.
See this image and copyright information in PMC

References

    1. Altice FL, Azbel L, Stone J, Brooks-Pollock E, Smyrnov P, Dvoriak S, & Vickerman P (2016). The perfect storm: Incarceration and the high-risk environment perpetuating transmission of HIV, hepatitis C virus, and tuberculosis in Eastern Europe and Central Asia. The Lancet, 388(10050), 1228–1248. 10.1016/S0140-6736(16)30856-X. - DOI - PMC - PubMed
    1. Arredondo J, Gaines T, Manian S, Vilalta C, Banuelos A, Strathdee SA, & Beletsky L (2018). The law on the streets: Evaluating the impact of Mexico’s drug decriminalization reform on drug possession arrests in Tijuana, Mexico. International Journal of Drug Policy, 54. 1–8. 10.1016/j.drugpo.2017.12.006. - DOI - PMC - PubMed
    1. Beletsky L, Wagner KD, Arredondo J, Palinkas L, Magis Rodríguez C, Kalic N, & Strathdee SA (2015). Implementing Mexico’s “Narcomenudeo ” drug law reform: A mixed methods assessment of early experiences among people who inject drugs. Journal of Mixed Methods Research, 10(4), 384–401. 10.1177/1558689815575862. - DOI
    1. Blach S, Zeuzem S, Manns M, Altraif I, Duberg A-S, Muljono DH, & Razavi H (2017). Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study. The Lancet Gastroenterology & Hepatology, 2(3), 161–176. 10.1016/S2468-1253(16)30181-9. - DOI - PubMed
    1. Blower SM, & Dowlatabadi H (1994). Sensitivity and uncertainty analysis of complex models of disease transmission: An HIV model, as an example. International Statistical Review /Revue Internationale de Statistique, 62(2), 229–243. 10.2307/1403510. - DOI

Substances